The Center's Recommendation: Antibiotics Should Not Be Taken in COVID Unless There Is Possibility Of Bacterial Infection

A updated guideline for the management of adult coronavirus patients released by the Centre advises against the use of antibiotics in Covid cases unless there is a clinical suspicion of bacterial infection.

The updated recommendations, which were released on Sunday in response to an increase in coronavirus infections, advised against treating adult COVID-19 patients in India with medications such hydroxychloroquine, molnupirvir, favipirvir, azithromycin, and doxycycline.

The clinical guideline protocol was revised during a meeting of the AIIMS/ICMR-COVID-19 National Working Group on January 5. Also, it has cautioned physicians against using convalescent plasma treatment.

"Until there is a clinical suspicion of bacterial illness, antibiotics should not be utilised. The possibility of COVID-19 co-infection with other endemic illnesses must be taken into account "The rules stated.

Remdesivir may also be taken into consideration for up to five days in moderate or severe disorders that are very susceptible to progressing. When a patient has moderate to severe illness with a high likelihood of progression and needs supplementary oxygen but is not on IMV or ECMO, it should be begun within 10 days of the beginning of symptoms.

The medication should not be given for more than five days and should not be administered at home or on patients who are not receiving oxygen assistance, according to the recommendations. Moreover, Tocilizumab should be taken into consideration in cases of fast advancing moderate or severe illness, ideally within 24-48 hours of the beginning of severe disease/ICU admission.

After 129 days, India had a one-day increase of nearly 1,000 new COVID-19 cases on Sunday. The nation recorded a 918 case increase on Monday, bringing the total number of active cases to 6,350.